Australian researchers say they can stop melanoma spreading

September 11, 2017
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

Researchers say a combination of new treatments can stop the world's deadliest form of skin cancer—melanoma—in its tracks and halt its spread to other organs.

Results from two international drug conducted by the Sydney-based Melanoma Institute Australia have proved successful in preventing the disease spreading in stage three patients whose tumours had been surgically removed.

Until now, these patients were at a high risk (40 to 70 percent) of the disease becoming advanced and fatal.

"Results from these suggest we can stop the disease in its tracks—effectively preventing it from spreading and saving lives," the institute's medical director Georgina Long said in research published in the New England Journal of Medicine Monday.

"Our ultimate goal of making a chronic rather than a terminal illness is now so much closer to being achieved."

One in every three cancers diagnosed is a skin , according to the World Health Organisation, with Australia having among the highest incidences of melanoma in the world. One Australian dies from it every five hours.

While 90 percent of people can be cured by having the primary cancer removed through surgery, it spreads in the other 10 percent because it is detected too late.

"These results will change the way we treat melanoma patients as well as their quality of life," added Long.

"Until now, Stage III melanoma patients who have had their tumours surgically removed have simply had to play the waiting game, to see if their melanoma would metastasise or spread.

"Living with such fear severely affected them and their loved ones."

The researchers conducted two 12-month trials, one immunotherapy-based and the other with targeted therapies. Both proved successful in preventing the disease spreading.

In one of them, targeted therapies (dabrafenib and trametinib) blocked the action of a particular gene, BRAF, which is a driver for melanoma.

It not only stopped stage three melanoma from recurring in those with tumours removed, but increased overall survival, the research showed.

The other trial treated with the immunotherapy nivolumab or ipilimumab—designed to reboot the immune system to attack . Results showed nivolumab decreased the chance of relapse.

"These clinical trials show we now have ammunition to prevent melanoma spreading and progressing, which until now was a critical area of behaviour where we had no control," said Long.

"This will change how melanoma is treated around the world, as we no longer have to passively wait to see if the melanoma spreads."

The clinical trial results are due to be presented to the European Society for Medical Oncology's annual congress in Spain this week.

Explore further: Combined immunotherapy could help control melanoma that has spread to the brain

More information: 1. Long G.V, et al. Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF-Mutated Melanoma. New England Journal of Medicine.

2. Weber, J. et al. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine.

Press release: phys.org/wire-news/266555381/a … s-tracks.html#ajTabs

Related Stories

Combined immunotherapy could help control melanoma that has spread to the brain

June 5, 2017
A combination of two immunotherapy drugs is safe to give to patients with melanoma, a type of skin cancer, that has spread to the brain, and could help control the disease.

Vitamin therapy may help prevent melanoma

August 9, 2017
A new review highlights the potential of nicotinamide (Vitamin B3) for preventing melanoma in high-risk individuals.

Surgery may be best for advanced melanoma

April 5, 2017
(HealthDay)—Surgery to remove melanoma—the deadliest form of skin cancer—can extend the lives of patients whose disease has spread to the abdomen area, new research suggests.

New drug shrinks brain tumours in melanoma patients

May 21, 2012
(Medical Xpress) -- Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today.

New therapies harness power of the immune system against cancer

June 2, 2014
New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used ...

Researchers find immunotherapy treatments better for advanced skin cancer

November 4, 2016
McMaster University researchers have found that for patients diagnosed in the late stages of one of the most common and deadly forms of skin cancer, treatment with a combination of immunotherapy options improves survival ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.